N
Centralnervesystemet
Parkinsons sygdom
Antiparkinsonmidler
Levodopa kombineret med decarboxylasehæmmer
Levodopa til inhalation
MAO-B-hæmmere
COMT-hæmmere
Levodopa, decarboxylasehæmmer og COMT-hæmmer i kombination
Dopaminagonister
Antikolinerge midler
Amantadin
Levodopa, decarboxylasehæmmer og COMT-hæmmer i kombination
N04BA
Revideret:
27.11.2024
Karen Østergaard
(Forfatter),
Dansk Neurologisk Selskab
Tove Henriksen
(Referent),
Dansk Selskab for Bevægeforstyrrelser
Indledning | Anvendelsesområder | Behandlingsvejledning | Revurdering af behandlingen | Præparatvalg | Doseringsforslag | Nedsat lever- og/eller nyrefunktion | Kontraindikationer | Forsigtighedsregler | Patientsikkerhed | Bivirkninger | Interaktioner | Graviditet | Amning | Forgiftning | Farmakodynamik | Farmakokinetik | Tilskud | Præparater | Referencer
Der henvises i øvrigt også til Levodopa kombineret med decarboxylasehæmmer og COMT-hæmmere for en oversigt over præparater med indholdsstofferne hver for sig.
For yderligere oplysninger om behandling af Parkinsons sygdom, se antiparkinsonmidler.
Præparater
| Indholdsstof | Navn og firma | Dispform og styrke | Pakning | Pris enh. | Pris DDD |
|---|---|---|---|---|---|
| Carbidopa Entacapon Levodopa |
Corbilta Orion Pharma
Udgået
11.05.2026
|
filmovertrukne tabletter 200 mg+50 mg+200 mg | 100 stk. (Nordic Prime) | ||
| Carbidopa Entacapon Levodopa |
Lecigon® Nordic Infucare
|
enteralgel 20+5+20 mg/ml | 7 x 47 ml | 23,55 | 529,96 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "G.L.Pharma" G.L. Pharma Nordic
|
filmovertrukne tabletter 100+25+200 mg | 100 stk. | 9,09 | 40,90 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "G.L.Pharma" G.L. Pharma Nordic
|
filmovertrukne tabletter 100+25+200 mg | 130 stk. | 2,91 | 13,08 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "G.L.Pharma" G.L. Pharma Nordic
|
filmovertrukne tabletter 150+37,5+200 mg | 100 stk. | 2,92 | 8,75 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "G.L.Pharma" G.L. Pharma Nordic
|
filmovertrukne tabletter 150+37,5+200 mg | 130 stk. | 4,42 | 13,26 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 50+12,5+200 mg | 100 stk. | 1,71 | 15,37 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 50+12,5+200 mg | 130 stk. | 3,37 | 30,29 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 75+18,75+200 mg | 100 stk. | 4,17 | 25,01 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 75+18,75+200 mg | 130 stk. | 9,12 | 54,74 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 100+25+200 mg | 100 stk. | ||
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 100+25+200 mg | 130 stk. | 2,93 | 13,20 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 125+31,25+200 mg | 100 stk | 3,05 | 10,99 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 125+31,25+200 mg | 130 stk. | 9,48 | 34,14 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 150+37,5+200 mg | 100 stk | 2,96 | 8,87 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 150+37,5+200 mg | 130 stk. | 4,45 | 13,34 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 200+50+200 mg | 100 stk. | 5,40 | 12,16 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 200+50+200 mg | 130 stk. | 11,82 | 26,60 |
| Carbidopa Entacapon Levodopa |
Levodopa/Carbidopa/Entacapone "Orion" Orion Pharma
|
filmovertrukne tabletter 175+43,75+200 mg | 100 stk | 4,62 | 11,88 |
| Carbidopa Entacapon Levodopa |
Pentiro STADA Nordic
|
filmovertrukne tabletter 100+25+200 mg | 100 stk. | 4,09 | 18,41 |
| Carbidopa Entacapon Levodopa |
Pentiro STADA Nordic
|
filmovertrukne tabletter 100+25+200 mg | 130 stk. | 2,80 | 12,59 |
| Carbidopa Entacapon Levodopa |
Pentiro STADA Nordic
|
filmovertrukne tabletter 150+37,5+200 mg | 100 stk. | 2,85 | 8,54 |
| Carbidopa Entacapon Levodopa |
Pentiro STADA Nordic
|
filmovertrukne tabletter 150+37,5+200 mg | 130 stk. | 4,33 | 12,99 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 100+25+200 mg | 100 stk. (Orifarm) | ||
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 100+25+200 mg | 100 stk. (2care4) | 14,19 | 63,86 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 150+37,5+200 mg | 100 stk. (Orifarm) | 3,09 | 9,26 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 150+37,5+200 mg | 100 stk. (Medartuum) | ||
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 200+50+200 mg | 100 stk. (Orifarm) | ||
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 200+50+200 mg | 100 stk. (Medartuum) | ||
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 200+50+200 mg | 100 stk. (2care4) | 11,74 | 26,42 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 75+18,75+200 mg | 100 stk. (2care4) | 4,16 | 24,93 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 125+31,25+200 mg | 100 stk. (Paranova) | 3,04 | 10,95 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 125+31,25+200 mg | 100 stk. (Ebb Medical) | 3,04 | 10,95 |
| Carbidopa Entacapon Levodopa |
Stalevo® Orion Pharma
|
filmovertrukne tabletter 125+31,25+200 mg | 100 stk.( 2care4) | 3,07 | 11,04 |
Referencer
1563. Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010; 68(1):18-27, https://pubmed.ncbi.nlm.nih.gov/20582993/ (Lokaliseret 10. december 2021)
4678. Stoessl AJ. Continuous dopaminergic therapy in Parkinson disease: time to stride back?. Ann Neurol. 2010; 68:3-5, https://www.ncbi.nlm.nih.gov/pubmed/20583222 (Lokaliseret 17. oktober 2023)
